Home / Community / News / News

News

09/25/2014 - 9:48am

Researchers from Dr. Matthew Disney's lab at the Scripps Research Institute of Florida recently published an article describing a new chemical they designed to inhibit the unhealthy repeat-containing RNA molecule seen in DM2.

08/20/2014 - 11:05am

New research on the impact of the mother's age on congenitally affected offspring.

07/23/2014 - 12:04pm

Researchers at the University of Illinois recently re-engineered small molecules to disrupt toxic RNA repeats involved in DM2.

07/23/2014 - 11:53am

The DMCRN was established a little over three years ago to evaluate potential DM treatments, prepare possible clinical trial sites and conduct important DM research studies.

07/09/2014 - 3:49pm

Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.) announced today that it has launched a Phase 1 clinical trial for IONIS-DMPKRX. IONIS-DMPKRX is designed to reduce the production of toxic dystrophia myotonic-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).

Partners

© Myotonic Dystrophy Foundation. All rights reserved.